durvalumab
FDA Approves Imfinzi for Muscle-Invasive Bladder Cancer
The FDA has approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, ...
MARCH 31, 2025
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer
The FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) ...
DECEMBER 5, 2024
Adding Checkpoint Inhibitor to Therapy Improves Overall Survival in Bladder Cancer
In patients with muscle-invasive bladder cancer (MIBC) eligible for neoadjuvant cisplatin-based chemotherapy ...
OCTOBER 16, 2024
FDA Approves Neoadjuvant/Adjuvant Imfinzi for Resectable NSCLC
The FDA has approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant ...
AUGUST 19, 2024
FDA Approves Imfinzi With Chemo for dMMR Primary Advanced or Recurrent Endometrial Cancer
The FDA has approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by ...
JUNE 17, 2024
Consolidation Immunotherapy in Limited-Stage Small Cell Lung Cancer Improves Overall Survival
After platinum-based chemoradiotherapy, a consolidation immunotherapy regimen significantly improved overall ...
JUNE 12, 2024
Novel First-Line Therapy’s OS Benefit for Liver Cancer Persists
Long-term overall survival in hepatocellular carcinoma with tremelimumab plus durvalumab treatment is durable, ...
NOVEMBER 27, 2023
Antibiotics Can Be Used During Durvalumab Treatment in Biliary Tract Cancer
Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based ...
FEBRUARY 20, 2023
New Treatment for Unresectable Hepatocellular Carcinoma
The FDA has approved AstraZeneca’s tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab ...
OCTOBER 24, 2022
Imfinzi Plus Chemotherapy Approved as First Immunotherapy Regimen for Advanced Biliary Tract Cancer
The FDA approved durvalumab (Imfinzi, AstraZeneca) for the treatment of adult patients with locally advanced or ...
SEPTEMBER 6, 2022
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 10, 2022
Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or ...
APRIL 6, 2020
